Correspondingly, CANA also attenuated hepatic steatosis in WD-fed MC4R-KO mice, after treatment for eight weeks, along with healthy adipose expansion, suggesting that the preventive effect on hepatic steatosis was due to the class effect(s) of SGLT2 inhibitors. Here, SLC5A2 is linked to fatty liver disease.